LG
LGVN.US Longeveron LLC
- Market cap
- USD 8.40M
- P/E
- -
- P/B
- 1.78x
- ROE
- -479.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LGVN.US undervalued?
Graham numberThe Graham number of Longeveron LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Longeveron LLC fundamental analysis
No fundamental analysis for Longeveron LLC yet.
Longeveron LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase…
Full company profileLongeveron LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Longeveron LLC annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 2.13M | 5.63M | 5.63M | 1.31M | 1.22M | 709K | 2.39M | 1.20M | 1.07M |
| Gross Profit | 681K | 1.83M | 1.83M | 590K | 497K | 221K | 1.88M | 803K | 689K |
| Operating Income | -6.36M | -3.78M | -3.78M | -17.5M | -18.0M | -21.0M | -16.5M | -23.3M | -24.2M |
| EBITDA | -5.59M | -2.95M | -2.93M | -16.1M | -17.9M | -20.5M | -15.0M | -21.5M | -21.9M |
| Net Income | -6.34M | -3.72M | -3.72M | -17.0M | -18.8M | -21.4M | -16.0M | -22.7M | -22.6M |
| EPS | -40 | -23 | -22 | -90 | -90 | -99 | -11 | -13 | -7.04 |
| Balance Sheet | |||||||||
| Total Assets | 10.5M | 10.6M | 9.24M | 42.8M | 27.4M | 12.1M | 25.6M | 10.3M | 12.0M |
| Total Liabilities | 3.71M | 6.14M | 7.28M | 5.31M | 6.91M | 5.34M | 3.67M | 4.59M | 7.31M |
| Shareholders' Equity | 6.81M | 4.45M | 1.96M | 37.5M | 20.5M | 6.74M | 21.9M | 5.68M | 4.71M |
| Cash & Short-term Investments | 4.03M | 1.87M | 816K | 35.0M | 19.7M | 5.36M | 19.2M | 4.66M | 7.25M |
| Total Debt | - | 4.14M | 4.14M | 3.14M | 2.61M | 2.04M | 1.45M | 824K | 412K |
| Cash Flow | |||||||||
| Operating Cash Flow | -5.18M | -2.39M | -2.36M | -9.64M | -14.0M | -19.0M | -13.9M | -18.6M | -16.9M |
| Capital Expenditure | 212K | 37.6K | 262K | 1.31M | 856K | 301K | 992K | 245K | 251K |
| Free Cash Flow | -5.39M | -2.43M | -2.63M | -10.9M | -14.8M | -19.3M | -14.9M | -18.9M | -17.2M |
| Ratios | |||||||||
| ROE | -93.0% | -83.7% | -190.1% | -45.5% | -91.9% | -317.7% | -73.0% | -400.1% | -479.7% |
| ROA | -60.2% | -35.2% | -40.3% | -39.9% | -68.7% | -177.3% | -62.5% | -221.3% | -188.0% |
| Net Profit Margin | -296.8% | -66.1% | -66.1% | -1,305.1% | -1,541.3% | -3,020.2% | -667.8% | -1,893.6% | -2,118.0% |
| Debt to Equity | - | 0.93x | 2.12x | 0.08x | 0.13x | 0.30x | 0.07x | 0.15x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Longeveron LLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 8.65M | 5.81 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 451K | 2.38 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Aug 27, 2026.
Who owns Longeveron LLC
- Insiders 14.80%
- Institutions 15.92%
- Public & others 69.29%
- Shares outstanding 3.23M
- Free float 2.36M
Top funds holding LGVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 36.1K | 1.11% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 13.4K | 0.41% | -0.21% | Sep 2026 |
| Abante Quant Value FI | 7.60K | 0.23% | -0.01% | Aug 2026 |
| Fidelity Total Market Index | 2.39K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.04K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding LGVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Millennium Management LLC | 1.35M | 4.16% | +203.07% | Jun 2026 |
| Logos Global Management LP | 1.29M | 3.96% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 581K | 1.79% | +7.25% | Jun 2026 |
| BlackRock Inc | 224K | 0.69% | -0.01% | Jun 2026 |
| Geode Capital Management, LLC | 204K | 0.63% | +0.07% | Jun 2026 |
| Jane Street Group LLC | 190K | 0.59% | +2.54% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 140K | 0.43% | +261.95% | Jun 2026 |
| Mariner Wealth Advisors LLC | 126K | 0.39% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 108K | 0.33% | -45.80% | Jun 2026 |
| Beacon Pointe Advisors, LLC | 100K | 0.31% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 58.6K | 0.18% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 56.0K | 0.17% | 0.00% | Jun 2026 |
| State Street Corp | 45.4K | 0.14% | 0.00% | Jun 2026 |
| Northern Trust Corp | 43.3K | 0.13% | +118.91% | Jun 2026 |
| Scotia Capital Inc | 30.0K | 0.09% | 0.00% | Jun 2026 |
| Capital Investment Advisory Services, LLC | 26.5K | 0.08% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 25.2K | 0.08% | 0.00% | Jun 2026 |
| Moneta Group Investment Advisors Inc | 21.3K | 0.07% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 20.6K | 0.06% | 0.00% | Jun 2026 |
| Accelerate Investment Advisors LLC | 14.3K | 0.04% | 0.00% | Jun 2026 |
Longeveron LLC company profile
- Company name
- Longeveron LLC
- Ticker
- LGVN.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- Life Science & Technology Park, Miami, FL, United States, 33136
- Phone
- 844 470 2550
- Website
- longeveron.com
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron LLC management
8- Dr. Joshua Michael Hare FACC, M.D.Co-Founder, Chief Science Officer & Executive Chairman · born 1963
- Mr. Paul T. Lehr J.D.General Counsel & Secretary · born 1968
- Mr. Stephen H. Willard Esq.CEO & Director · born 1961
- Mr. Nirav Suresh Jhaveri C.F.A., M.B.A.CFO and Principal Financial & Accounting Officer · born 1978
- Mr. Devin BlassCTO and Senior VP of Chemistry, Manufacturing & Controls · born 1986
- Ms. Lisa McClain-MossVice President of Manufacturing · born 1971
- Ms. Marie WashburnVP & Corporate Controller · born 1975
- Mr. Brian G Rash Ph.D.Vice President of Research & Discovery